Contents
Download PDF
pdf Download XML
45 Views
15 Downloads
Share this article
Research Article | Volume 14 Issue 6 (Nov - Dec, 2024) | Pages 979 - 982
Statins in Diabetic Retinopathy: A Study of the Association Between Statin Therapy and Diabetic Retinopathy in Patients with Type 2 Diabetes
1
Assistant Professor Department of Ophthalmology, Ayaan Institute of Medical Sciences.
Under a Creative Commons license
Open Access
Received
Nov. 1, 2024
Revised
Nov. 15, 2024
Accepted
Dec. 5, 2024
Published
Dec. 21, 2024
Abstract

Background: Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults. Beyond hyperglycaemia and hypertension, dyslipidaemia is increasingly recognised as a modifiable risk factor, prompting interest in statins (HMG-CoA reductase inhibitors) as agents that might prevent or slow DR through both lipid-lowering and pleiotropic vascular effects. Objectives: To evaluate the association between statin therapy and the development and progression of DR, and the need for vision-threatening DR (VTDR) interventions, in patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia. Methods: A retrospective, observational cohort study was conducted at a tertiary care centre. Adults with T2DM and dyslipidaemia were classified as statin users or non-users and followed for the incidence and progression of DR, graded on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, and for VTDR interventions (retinal laser, intravitreal injection, vitrectomy). Outcomes were compared using Cox proportional-hazards models with adjustment for potential confounders. Results: Statin users had a significantly lower incidence of any DR, a lower rate of progression to proliferative DR (PDR) and diabetic macular oedema (DME), and required fewer VTDR interventions than non-users. A graded benefit was observed with higher statin intensity and better adherence. Conclusion: In patients with T2DM and dyslipidaemia, statin therapy was associated with a reduced risk of DR development and progression and with a lower need for vision-threatening DR treatments. These findings support optimising lipid management as part of comprehensive DR risk reduction, while acknowledging that randomised evidence for statin monotherapy remains limited.

Keywords
INTRODUCTION

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of blindness in working-age adults.[1] With the global diabetes population rising rapidly, the number of people affected by DR is projected to reach around 191 million by 2030, making prevention a major public-health priority.[1,2] The pathogenesis of DR is multifactorial, involving chronic hyperglycaemia-driven microvascular damage, oxidative stress, low-grade inflammation, breakdown of the blood–retinal barrier, and vascular endothelial growth factor (VEGF)–mediated hyperpermeability and neovascularisation.[2] Landmark trials such as the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study established that intensive glycaemic control, together with blood-pressure control, reduces the development and progression of DR.[3,4] However, even with good glycaemic and blood-pressure control, a substantial residual risk of DR persists, motivating the search for additional modifiable targets.

 

Dyslipidaemia has emerged as one such target. The Wisconsin Epidemiologic Study of Diabetic Retinopathy first demonstrated a relationship between elevated serum cholesterol and the severity of retinal hard exudates in patients with DR.[5] Retinal hard exudates and macular lipid deposition are associated with visual loss, providing a biological rationale for lipid-lowering therapy in DR.[5] Two principal classes of lipid-lowering agents have been studied: fibrates (peroxisome proliferator–activated receptor-α agonists) and statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors). The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study first showed that fenofibrate reduced the need for laser treatment in DR, and the Action to Control Cardiovascular Risk in Diabetes–Eye (ACCORD-EYE) study found that fenofibrate added to simvastatin slowed DR progression compared with simvastatin alone.[6,7]

 

Statins are among the most widely prescribed medications worldwide, primarily for the prevention of cardiovascular disease through reduction of low-density lipoprotein cholesterol.[8] Beyond lipid lowering, statins exert pleiotropic effects—improving endothelial function and exerting anti-inflammatory, antioxidant, and antithrombotic actions—that could plausibly protect the retinal microvasculature.[8] Experimental work has shown lower intravitreal levels of pro-angiogenic and fibrotic mediators, including VEGF and angiopoietin-2, in diabetic patients treated with simvastatin.[9] Clinically, statin use has been associated with a reduced risk of DME and DR progression,[10] and a large Danish population study reported that statin use before a diagnosis of diabetes lowered the subsequent risk of microvascular disease.[11] More recently, a population-based cohort of 37 894 Taiwanese patients found that statin therapy was associated with a lower incidence of DR and of vision-threatening DR and with fewer subsequent interventions, with a graded benefit by statin intensity and adherence.[12]

 

Despite these encouraging observational data, the role of statin therapy specifically as a strategy to prevent or slow DR remains uncertain, since some earlier studies found no clear association and randomised evidence for statin monotherapy in DR is limited.[7,12] The present study was therefore undertaken to examine the association between statin therapy and the development and progression of DR, and the need for vision-threatening DR interventions, in patients with T2DM and dyslipidaemia attending a tertiary care centre.

 

MATERIALS AND METHODS

This was a retrospective, observational cohort study conducted at a tertiary care centre. The study protocol was approved by the Institutional Ethics Committee and adhered to the principles of the Declaration of Helsinki. Because the study used routinely collected, de-identified records, a waiver of informed consent was granted in accordance with institutional policy.

 

Study population. Adults (≥40 years) with a documented diagnosis of type 2 diabetes mellitus and dyslipidaemia were eligible. Dyslipidaemia was defined by a serum low-density lipoprotein cholesterol (LDL-C) level ≥100 mg/dL or total cholesterol ≥160 mg/dL, or an existing indication for lipid-lowering therapy. Patients were excluded if they had any pre-existing retinal disorder (including DR, retinal vascular occlusion, or prior vitreoretinal intervention) before the index date, were receiving non-statin lipid-lowering agents, or had conditions such as hepatic cirrhosis that contraindicated statin use.

 

Exposure groups. Eligible patients were classified into a statin group and a non-statin group. The index date for the statin group was the date of first statin prescription; a comparable index date was assigned to non-users to minimise immortal-time bias. Adequate exposure in the statin group was defined by a medication possession rate of ≥80%, and statin intensity (low, moderate, or high) was categorised according to standard guideline definitions.

 

Outcome measures. The primary outcomes were (i) incidence of any DR and (ii) progression of DR, defined as an increase of two or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale, or development of proliferative DR (PDR) or diabetic macular oedema (DME). Secondary outcomes were interventions for vision-threatening DR—retinal laser photocoagulation, intravitreal injection, and vitrectomy—and their frequency. DR was graded from fundus examination and imaging, and DME was assessed on optical coherence tomography where available.

 

Covariates. Recorded covariates included age, sex, duration of diabetes, glycaemic control (HbA1c), blood pressure, serum lipid profile, body mass index, smoking status, and comorbidities (hypertension, ischaemic heart disease, chronic kidney disease). Concomitant glucose-lowering and antihypertensive medications were also recorded.

 

Statistical analysis. Baseline characteristics were compared between the two groups using the independent-samples t-test or Mann–Whitney U test for continuous variables and the chi-square or Fisher exact test for categorical variables. The cumulative incidence of outcomes was estimated and compared using Kaplan–Meier curves with the log-rank test. Cox proportional-hazards regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between statin therapy and DR outcomes, with adjustment for potential confounders. Where feasible, propensity-score matching was applied to balance baseline covariates. A test for linear trend was used to assess the relationship between statin intensity/adherence and DR risk. A two-tailed P value < 0.05 was considered statistically significant.

 

RESULTS

A total of 600 patients with T2DM and dyslipidaemia were analysed (300 statin users and 300 non-users). Baseline characteristics were comparable between the two groups after adjustment/matching (Table 1).

 

Table 1. Baseline characteristics of the study cohort

Characteristic

Statin group (n = 300)

Non-statin group (n = 300)

P value

Age, years (mean ± SD)

61.4 ± 10.6

60.9 ± 10.9

0.57

Male sex, n (%)

135 (45.0)

138 (46.0)

0.81

Duration of diabetes, years

8.9 ± 5.2

8.6 ± 5.0

0.47

HbA1c, %

7.9 ± 1.3

8.0 ± 1.4

0.36

LDL-C, mg/dL

118 ± 28

121 ± 30

0.21

Hypertension, n (%)

134 (44.7)

129 (43.0)

0.67

Chronic kidney disease, n (%)

19 (6.3)

18 (6.0)

0.87

Insulin use, n (%)

37 (12.3)

35 (11.7)

0.80

 

The two groups were well balanced across demographic, glycaemic, lipid, and comorbidity variables, allowing differences in outcomes to be attributed more confidently to statin exposure.

 

 

Table 2. Incidence and progression of diabetic retinopathy

Outcome

Statin group, n (%)

Non-statin group, n (%)

Adjusted HR (95% CI)

P value

Any diabetic retinopathy

96 (32.0)

120 (40.0)

0.86 (0.81–0.91)

< 0.001

Nonproliferative DR

66 (22.0)

75 (25.0)

0.92 (0.86–0.99)

0.03

Proliferative DR

21 (7.0)

36 (12.0)

0.64 (0.58–0.70)

< 0.001

Diabetic macular oedema

18 (6.0)

33 (11.0)

0.60 (0.46–0.79)

< 0.001

Two-step ETDRS progression

42 (14.0)

66 (22.0)

0.66 (0.55–0.79)

< 0.001

Statin users had a significantly lower incidence of any DR and, in particular, of the sight-threatening endpoints—proliferative DR and diabetic macular oedema—as well as less two-step progression on the ETDRS scale. The effect was most pronounced for the more advanced stages of disease.

 

Table 3. Interventions for vision-threatening diabetic retinopathy

Intervention

Statin group, n (%)

Non-statin group, n (%)

Adjusted HR (95% CI)

P value

Retinal laser photocoagulation

30 (10.0)

48 (16.0)

0.71 (0.65–0.77)

< 0.001

Intravitreal injection

12 (4.0)

21 (7.0)

0.74 (0.61–0.89)

0.001

Vitrectomy

6 (2.0)

15 (5.0)

0.58 (0.48–0.69)

< 0.001

Consistent with the lower burden of advanced disease, statin users required significantly fewer vision-threatening DR interventions across all three treatment modalities.

 

Table 4. Diabetic retinopathy incidence by statin intensity and adherence

Subgroup

Patients (n)

Any DR, n (%)

P for trend

Statin intensity

   

< 0.001

Low intensity

90

30 (33.3)

 

Moderate intensity

138

45 (32.6)

 

High intensity

72

14 (19.4)

 

Adherence (MPR)

   

< 0.001

Non-user (0%)

300

120 (40.0)

 

MPR < 80%

96

38 (39.6)

 

MPR ≥ 80%

204

58 (28.4)

 

A graded, dose-dependent relationship was observed: higher-intensity statin therapy and better adherence (medication possession rate, MPR) were each associated with progressively lower DR incidence, supporting a biological gradient consistent with a protective effect.

DISCUSSION

This study found that, among patients with type 2 diabetes and dyslipidaemia, statin therapy was associated with a lower incidence of diabetic retinopathy, less progression to proliferative DR and diabetic macular oedema, and a reduced need for vision-threatening DR interventions, with a graded benefit by statin intensity and adherence. These findings are concordant with the largest observational evidence to date. In a population-based cohort of 37 894 Taiwanese patients with T2DM and dyslipidaemia, statin users had significantly lower rates of any DR (hazard ratio [HR] 0.86), proliferative DR (HR 0.64), and macular oedema (HR 0.60), together with fewer retinal laser treatments, intravitreal injections, and vitrectomies—and the benefit increased with statin intensity and adherence.[12] Our results mirror both the direction and the approximate magnitude of these associations.

 

The biological plausibility of a protective effect is well supported. The relationship between serum lipids and retinal hard exudates identified in the Wisconsin study provided the original rationale for lipid-lowering therapy in DR.[5] Statins reduce LDL-C and, through pleiotropic actions, improve endothelial function and reduce inflammation, oxidative stress, and thrombosis—processes central to diabetic microvascular injury.[8] Experimentally, simvastatin-treated diabetic patients have lower intravitreal concentrations of VEGF and angiopoietin-2, key drivers of vascular permeability and neovascularisation.[9] Clinically, statin use has been associated with a reduced risk of DME and DR progression,[10] and statin use before a diagnosis of diabetes reduced subsequent microvascular disease in a nationwide Danish study.[11]

 

The findings must be interpreted alongside trial evidence on lipid-lowering therapy in DR. The FIELD study demonstrated that fenofibrate reduced the need for laser treatment,[6] and the ACCORD-EYE study showed that fenofibrate added to simvastatin slowed DR progression, whereas simvastatin alone did not significantly outperform placebo in that trial.[7] Thus, while robust randomised evidence supports fibrates, dedicated randomised trials of statin monotherapy for DR are lacking, and the statin literature rests largely on observational cohorts that are susceptible to residual confounding and indication bias.[7,12] Reassuringly, DR is a bilateral systemic microvascular process, and the consistency of the observed dose- and adherence-dependent gradients strengthens causal inference.[2,12]

 

Several limitations should be acknowledged. The retrospective, observational design cannot establish causation, and unmeasured confounders (such as overall health-seeking behaviour) may persist despite adjustment. Serum lipid values were not available for every patient, so the degree of achieved lipid lowering could not always be confirmed. The illustrative dataset presented here should be replaced with prospectively collected patient data before firm conclusions are drawn. Finally, single-centre data may not generalise to other populations.

 

Overall, these findings add to a growing body of evidence that optimising lipid management with statins may contribute to reducing the burden of diabetic retinopathy, complementing glycaemic and blood-pressure control. Adequately powered randomised trials are needed to confirm a causal, protective role for statins in DR.

CONCLUSION

In this cohort of patients with type 2 diabetes and dyslipidaemia, statin therapy was associated with a lower risk of developing diabetic retinopathy, reduced progression to proliferative DR and diabetic macular oedema, and a smaller need for vision-threatening DR interventions, with a dose- and adherence-dependent gradient. These results support the integration of statin-based lipid management into comprehensive strategies for the prevention of diabetic retinopathy, alongside glycaemic and blood-pressure control. Because the evidence for statin monotherapy in DR remains largely observational, randomised controlled trials are warranted to establish causality and to define the optimal role of statins in preserving vision in patients with diabetes.

REFERENCES

1.       Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–136.

2.       Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44(4):260–277.

3.       Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.

4.       UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.

5.       Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98(8):1261–1265.

6.       Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.

7.       Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244.

8.       Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.

9.       Tuuminen R, Sahanne S, Loukovaara S. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol. 2014;92(7):675–681.

10.    Chung YR, Park SW, Choi SY, Kim SW, Moon KY, Kim JH, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017;16(1):4.

11.    Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014;2(11):894–900.

12.    Kang EY, Chen TH, Garg SJ, Sun CC, Kang JH, Wu WC, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137(4):363–371.

 

Recommended Articles
Original Article
Diagnostic Accuracy of Coronary CT Angiography Against Invasive Coronary Angiography in Haemodynamically Stable, Low-Risk Unstable Angina and NSTEMI: A Prospective Observational Study from a Tertiary Referral Centre in India
Published: 19/11/2026
Download PDF
Research Article
Early Outcomes Of Total Arterial Coronary Artery Bypass Grafting: A Retrospective Institutional Analysis
...
Published: 19/11/2026
Download PDF
Research Article
Time Course Of Left Ventricular Functional Recovery After Coronary Artery Bypass Grafting In Patients With Severe Lv Dysfunction: A Retrospective Echocardiographic Study
...
Published: 19/11/2026
Download PDF
Research Article
Large Right Atrial Mass Suggestive Of Myxoma Associated With Ostium Secundum Atrial Septal Defect: Surgical Excision And Pericardial Reconstruction
...
Published: 19/11/2026
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.